In heart failure as well as in chronic kidney disease sodium-glucosecotransporter 2 (SGLT2) inhibitors have changed the landscape of medical therapy.Originally developed for use in diabetes, an unforeseen cardiovascular benefitextended SGLT2 inhibitor use from antihyperglycemic agents to cardiovascular andrenal risk modifying agents. Here, SLC5A2 is linked to diabetes mellitus.